Ventyx Biosciences (VTYX) Competitors $2.02 +0.13 (+6.88%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VTYX vs. HUMA, CRGX, PHVS, ANNX, KROS, MREO, RAPP, DNA, TRDA, and ORKAShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Humacyte (HUMA), CARGO Therapeutics (CRGX), Pharvaris (PHVS), Annexon (ANNX), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), Ginkgo Bioworks (DNA), Entrada Therapeutics (TRDA), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Humacyte CARGO Therapeutics Pharvaris Annexon Keros Therapeutics Mereo BioPharma Group Rapport Therapeutics Ginkgo Bioworks Entrada Therapeutics Oruka Therapeutics Ventyx Biosciences (NASDAQ:VTYX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings. Does the MarketBeat Community favor VTYX or HUMA? Humacyte received 3 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 66.67% of users gave Humacyte an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformVentyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% HumacyteOutperform Votes3466.67% Underperform Votes1733.33% Does the media prefer VTYX or HUMA? In the previous week, Humacyte had 30 more articles in the media than Ventyx Biosciences. MarketBeat recorded 44 mentions for Humacyte and 14 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.66 beat Humacyte's score of 0.17 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 8 Very Positive mention(s) 5 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, VTYX or HUMA? Ventyx Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Which has stronger valuation and earnings, VTYX or HUMA? Humacyte has higher revenue and earnings than Ventyx Biosciences. Humacyte is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$192.96M-$2.36-0.86Humacyte$1.57M353.53-$110.78M-$1.34-3.29 Do analysts rate VTYX or HUMA? Ventyx Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 395.05%. Humacyte has a consensus target price of $13.71, indicating a potential upside of 210.98%. Given Ventyx Biosciences' higher probable upside, analysts plainly believe Ventyx Biosciences is more favorable than Humacyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is VTYX or HUMA more profitable? Ventyx Biosciences' return on equity of -54.94% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -54.94% -50.01% Humacyte N/A -942.81%-93.82% Do insiders & institutionals believe in VTYX or HUMA? 97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by company insiders. Comparatively, 11.2% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryHumacyte beats Ventyx Biosciences on 10 of the 17 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.83M$6.58B$5.35B$9.06BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.869.8389.4817.34Price / SalesN/A307.731,251.60134.53Price / CashN/A61.4443.7535.97Price / Book0.496.055.324.80Net Income-$192.96M$154.62M$122.60M$224.91M7 Day Performance-2.88%-1.70%0.88%1.90%1 Month Performance-12.17%2.75%4.81%5.08%1 Year Performance6.32%2.60%27.90%21.15% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences3.0954 of 5 stars$2.02+6.9%$10.00+395.0%-3.3%$142.83MN/A-0.8630Analyst ForecastAnalyst RevisionNews CoverageHUMAHumacyte2.8239 of 5 stars$4.36-5.4%$13.71+214.5%+70.9%$548.75M$1.57M-3.25150Short Interest ↑Analyst RevisionCRGXCARGO Therapeutics1.5858 of 5 stars$11.89-11.9%$31.80+167.5%-35.9%$547.27MN/A-2.79116Analyst RevisionPHVSPharvaris2.3332 of 5 stars$16.94-4.8%$39.25+131.7%-34.5%$539.37MN/A-6.0530Positive NewsGap DownHigh Trading VolumeANNXAnnexon2.14 of 5 stars$4.86+0.6%$15.80+225.1%-8.7%$518.05MN/A-4.6360Short Interest ↑KROSKeros Therapeutics3.1774 of 5 stars$12.78-12.2%$75.00+486.9%-79.5%$517.68M$651,000.00-2.45100Analyst ForecastShort Interest ↑News CoverageGap DownMREOMereo BioPharma Group2.1968 of 5 stars$3.31-6.8%$7.83+136.7%-9.1%$513.53M$1M0.0040RAPPRapport Therapeutics2.2933 of 5 stars$13.91-6.1%$35.00+151.6%N/A$508.77MN/A0.00N/ADNAGinkgo Bioworks0.6472 of 5 stars$8.79-10.1%$4.58-48.0%N/A$505.24M$217.11M-0.671,218TRDAEntrada Therapeutics2.593 of 5 stars$13.38-8.7%$25.67+91.8%-18.2%$500.68M$215.23M8.42110Positive NewsORKAOruka Therapeutics2.509 of 5 stars$14.11-10.2%$43.17+205.9%N/A$493.84MN/A-2.25N/A Related Companies and Tools Related Companies Humacyte Competitors CARGO Therapeutics Competitors Pharvaris Competitors Annexon Competitors Keros Therapeutics Competitors Mereo BioPharma Group Competitors Rapport Therapeutics Competitors Ginkgo Bioworks Competitors Entrada Therapeutics Competitors Oruka Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTYX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTYX Stock Alerts